small win: pentadecapeptide stopped being a problem at week 74
Reporting in. small win: pentadecapeptide stopped being a problem at week 74.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
The evidence base, described honestly, which almost no summary of it does.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Do you have the mass spectrum?
the tendon claims are the most repeated and the least evidenced
the tendon claims are the most repeated and the least evidenced
Adding the standing caveat — research material is not approved for human use, wherever you are.
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.
regulatory status varies by jurisdiction and it has moved recently
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
the human evidence is thin and the rodent evidence is not
Reconstituted or powder, and how long has it been in solution?
Bought small, tested identity first, and only then thought about anything else. That order felt right.
Citation requested rather than removal. A claim here should say whether its source is preclinical.
a fifteen-residue peptide is easy to make and easy to make badly
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
- 1The evidence base, described honestly, which almost no summary of it does.…7 comments in this branch · started by u/chain_confirm_c